Current and emerging techniques for ANCA detection in vasculitis

Nature Reviews Rheumatology

Volumn 10, Issue 8, 2014, Pages 494-501

  Csernok, Elena ^a   Moosig, Frank ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR;

ANCA ASSOCIATED VASCULITIS; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIC GRANULOMA; HUMAN; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; MICROSCOPIC POLYANGIITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; VASCULITIS; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOOD; CHURG-STRAUSS SYNDROME; FLUORESCENT ANTIBODY TECHNIQUE; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; PROCEDURES;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; CHURG-STRAUSS SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOLOGIC FACTORS; MICROSCOPIC POLYANGIITIS; MYELOBLASTIN; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84905435530     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.78     Document Type: Review

References (43)

1. Davies, D. J. et al. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br. Med. J. (Clin. Res. Ed.) 285, 606 (1982).
2. Van der Woude, F. J., Rasmussen, N. & Lobatto, S. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1, 425-429 (1985).
3. Jennette, J. C. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37, 187-192 (1994).
4. Jennette, J. C. et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 65, 1-11 (2013).
5. Schmitt, W. H. & van der Woude, F. J. Clinical applications of antineutrophil cytoplasmic antibody testing. Curr. Opin. Rheumatol. 16, 9-17 (2004).
6. Csernok, E., Lamprecht, P. & Gross, W. L. Diagnostic significance of ANCA in vasculitis. Nat. Clin. Pract. Rheumatol. 2, 174-175 (2006).
7. Cohen Tervaert, J. W. & Damoiseaux, J. Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin. Rev. Allergy Immunol. 43, 211-219 (2012).
8. Specks, U. Controversies in ANCA testing. Cleve. Clin. J. Med. 79 (Suppl. 3), S7-S11 (2012).
9. Savige, J. et al. International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am. J. Clin. Pathol. 111, 507-513 (1999).
10. Savige, J. et al. Addendum to the International Consensus Statement on testing and reporting of anti-neutrophil cytoplasmatic antibodies. Quality control guidelines, comments and recommendations for testing in other autoimmune diseases. Am. J. Clin. Pathol. 120, 312-314 (2003).
11. Hagen, E. C. et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 53, 743-753 (1998).
12. Csernok, E. & Holle, J. U. Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA-evidence-based immunology? Autoimmunity Highlights 1, 39-43 (2010).
13. Russell, K. A., Wiegert, E., Schroeder, D. R., Homburger, H. A. & Specks, U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin. Immunol. 103, 196-203 (2002).
14. Willitzki, A. et al. New platform technology for comprehensive serological diagnostics of autoimmune diseases. Clin. Dev. Immunol. http://dx.doi.org/10.1155/2012/284740 (2012).
15. Boomsma, M. M. et al. Image analysis: a novel approach for the quantification of ANCA levels in patients with Wegener's granulomatosis. J. Immunol. Methods 274, 27-35 (2003).
16. Melegari, A. et al. A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun. Rev. 11, 713-716 (2012).
17. Knütter, I. et al. Automated interpretation of ANCA patterns-a new approach in the serology of ANCA-associated vasculitis. Arthritis Res Ther. 14, R271 (2012).
18. Damoiseaux, J., Mallet, K., Vaessen. M., Austen, J. & Cohen Tervaert, J. W. Automatic reading of ANCA-slides: evaluation of the AKLIDES system. Clin. Dev. Immunol. http://dx.doi.org/10.1155/2012/762874 (2012).
19. Franssen, C. et al. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J. Intern. Med. 244, 209-216 (1998).
20. Schönermarck, U., Lamprecht, P., Csernok, E. & Gross, W. L. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) 40, 178-184 (2001).
21. Hauer, H. A. et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 61, 80-89 (2002).
22. Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214-223 (2012).
23. Holle, J. U., Hellmich, B., Backes, M., Gross, W. L. & Csernok, E. Variations in performance characteristics of commercial enzyme immunoassay kits of the detection of antineutrophil cytoplasmatic antibodies: what is the optimal cut-off? Ann. Rheum. Dis. 64. 1773-1779 (2005).
24. Westman, K. et al. Clinical evaluation of a capture-ELISA for PR3-ANCA. Kidney Int. 53, 1230-1236 (1998).
25. Sun, J. et al. Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunocomplexes. J. Immunol. Meth. 211, 111-123 (1998).
26. Csernok, E. et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies against proteinase-3 in Wegener's granulomatosis: first results from a multicenter study. Rheumatology (Oxford) 43, 174-180 (2004).
27. Gisslen, K., Wieslander, J., Westberg, K. & Herlitz, H. Relationship between anti-neutrophil cytoplasmatic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J. Int. Med. 251, 129-135 (2002).
28. Hellmich, B., Csernok, E., Fredenhagen, G. & Gross, W. L. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin. Exp. Rheumatol. 25 (1 Suppl. 44), S1-S5 (2007).
29. Holle, J. U., Csernok, E., Fredenhagen, G. & Gross, W. L. Clinical evaluation of hsPR3-ANCA ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3. Ann. Rheum. Dis. 69, 468-469 (2010).
30. Damoiseaux, J. et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. Ann. Rheum. Dis. 68, 228-233 (2009).
31. Roggenbuck, D. et al. High sensitivity detection of autoantibodies against proteinase 3 by a novel third-generation enzyme-linked immunoabsorbent assay. Ann. NY Acad Sci. 1173, 41-46 (2009).
32. Holle, J. U., Hermann K., Gross, W. L. & Csernok, E. Comparative analysis of different commercial ELISA systems for detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin. Exp. Rheumatol. 30 (Suppl. 70), S66-S69 (2012).
33. Radice, A., Bianchi, L., Maggiore, U., Vaglio, A. & Sinico, R. A. Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener's). Clin. Chem. Lab. Med. 51, 2141-2149 (2013).
34. Vermeersch, P. et al. Determination of anti-neutrophil cytoplasmic antibodies in small vessel vasculitis: comparative analysis of different strategies. Clin. Chim. Acta. 397, 77-81 (2008).
35. Damoiseaux, J. et al. EUROPLUS ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis. J. Immunol. Meth. 348, 67-73 (2009).
36. Trevisin, M., Pollock, W. & Savige, J. Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease. J. Immunol. Meth. 336, 104-112 (2008).
37. Finkielman, J. D. et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am. J. Med. 120, 643.e9-643.e14 (2007).
38. Westman, K. W. et al. Rapid screening assay for anti-GBM antibody and ANCAs; an important tool for the differential diagnosis of pulmonary renal syndromes. Nephrol. Dial. Transplant. 12, 1863-1868 (1997).
39. Tomasson, G. et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis: a meta-analysis. Rheumatology (Oxford) 51, 100-109 (2012).
40. McLaren, J. S., Stimson, R. H., McRorie, E. R., Coia, J. E. & Luqmani, R. A. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM 94, 615-621 (2001).
41. Mandl, L. A. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch. Intern. Med. 162, 1509-1514 (2002).
42. Sinclair, D., Saas M. & Stevens, J. M. The effect of a symptom related "gating policy" on ANCA requests in routine clinical practice. J. Clin. Pathol. 57, 131-134 (2004).
43. Arnold, D. F. et al. Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients. J. Clin. Pathol. 63, 678-680 (2010).